Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

59.12
-0.4600-0.77%
Post-market: 59.140.0160+0.03%19:59 EDT
Volume:9.25M
Turnover:548.64M
Market Cap:120.35B
PE:13.01
High:59.79
Open:58.88
Low:58.74
Close:59.58
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.73
T/O Rate:0.46%
Dividend:2.51
Dividend Rate:4.25%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.39
PE(LYR):17.09

Loading ...

Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Veeva Systems (VEEV) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Yesterday

BofA Securities Adjusts Bristol-Myers Squibb Price Target to $66 From $71

MT Newswires Live
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Bristol-Myers Squibb (BMY) Receives a Buy from J.P. Morgan

TIPRANKS
·
Oct 08

Cantor Fitzgerald Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

TIPRANKS
·
Oct 08

Bristol Myers’ zenbexus in combination shows efficacy in Phase 3 myeloma trial

TIPRANKS
·
Oct 08

Bristol Myers Squibb Says Zenbexus Combo Cuts Multiple Myeloma Progression Risk 51% in Phase 3 Excaliber-RRMM Trial

Reuters
·
Oct 08

Bristol Myers Squibb Announces Zenbexustm (Iberdomide) in Combination with Daratumumab and Dexamethasone (Zdd) Demonstrates Superior Progression-Free Survival VS. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

THOMSON REUTERS
·
Oct 08

Bristol-Myers Squibb Company - Excaliber Study Shows Pfs Hazard Ratio of 0.49 vs Standard of Care

THOMSON REUTERS
·
Oct 08

Bristol-Myers Squibb Company - Zenbexus Safety Profile Consistent with Previously Reported Findings

THOMSON REUTERS
·
Oct 08

Bristol-Myers Squibb Company - Zdd Median Pfs 42 Months vs 20 Months for Dvd; 51% Risk Reduction

THOMSON REUTERS
·
Oct 08

Bristol-Myers Squibb Company - Serious Adverse Reactions in 58.3% and Fatal in 4.9% of Zenbexus Patients

THOMSON REUTERS
·
Oct 08

Bristol-Myers Squibb is Maintained at Underweight by Morgan Stanley

Dow Jones
·
Oct 07

Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb to $41 From $40

MT Newswires Live
·
Oct 07

Vir Names David Liu Chief Medical Officer Effective Oct. 12, 2026

Reuters
·
Oct 07

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Oct 07

Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?

Simply Wall St.
·
Oct 07

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 07

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Bristol Myers Squibb Co. Stock Sheds 3.8%, Underperforms Peers

Dow Jones
·
Oct 06